Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%

NCT03212963 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's Decision

Conditions

Plaque Psoriasis

Interventions

DRUG: Halobetasol Topical Lotion

Sponsor

Sun Pharmaceutical Industries Limited